Black Diamond Therapeutics Inc (BDTX) Stock Price, Quote & News

Company Profile

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 1 clinical trial to treat glioblastoma. It is also develo...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 252 0848

Website: www.blackdiamondtherapeutics.com

Address:

One Main Street, 14th Floor, Cambridge, United States

Rickyrickz70 Nov. 14 at 3:14 PM

$BDTX Silevertinib has a lot of potential, but it's pretty sure that the FDA will ask them to do a phase III study... They will need some extra cash. For me this stock is a follow and I'll patiently wait before buying

0 · Reply

frankwa Nov. 14 at 12:48 PM

$BDTX do we think this is why the fall yesterday or think its for the future? Black Diamond has filed a mixed securities shelf of up to US$500 million and an additional common stock offering of up to US$150 million at this time.

0 · Reply

garbageshort Nov. 14 at 5:12 AM

$BDTX lolz... Another pig

1 · Reply

100K2022 Nov. 14 at 2:00 AM

$BDTX blood red market and the news came out after hours and it’s not selling off, not worried

0 · Reply

100K2022 Nov. 14 at 1:49 AM

$BDTX not panicking yet

0 · Reply

garbageshort Nov. 14 at 1:32 AM

$BDTX @StockRegulationBot is screwed

0 · Reply

isaacwilliams33 Nov. 14 at 12:08 AM

$BDTX phase2 data

1 · Reply

garbageshort Nov. 13 at 11:37 PM

$BDTX dilution before data .. burning the shareholders.... Bring it below 2

1 · Reply

DARKP00L Nov. 13 at 10:39 PM

$BDTX 17:29 on Nov. 13 2025 Black Diamond Therapeutics Files For Mixed Shelf Of Up To $500M; In Addition, Common Stock Offering Of Up To $150M #tradeideas

1 · Reply